12:00 AM
May 07, 2012
 |  BC Week In Review  |  Company News  |  Other News

Exelixis cancer news

Exelixis said it received approval of 12 clinical trials of cancer compound cabozantinib under a November research agreement with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP). The company now plans to conduct four randomized Phase II trials of cabozantinib in first-line renal cell carcinoma (RCC), second-line hepatocellular carcinoma (HCC), platinum-resistant or refractory ovarian cancer and second-line non-small cell lung cancer...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >